- Top Page
ATOX and Orano renew joint venture agreement
On July 18, 2019, Atox and Orano renewed their joint venture agreement. ANADEC decides to step up its commitment to help Japan’s D&D business. Read more
“Fukushima Marché” held at ATOX head office in Shiba today
As part of its efforts to support the reconstruction of Fukushima, ATOX hosted a “Fukushima Marché” (market) today.
ATOX receives Letter of Appreciation from Ministry of Economy, Trade and Industry
On April 16, 2019, the ATOX Fukushima Reconstruction Branch was awarded a Letter of Appreciation by the Ministry of Economy, Trade and Industry.
Three “site caravan” events held
Since November 2018 ATOX has held three “site caravans” for nuclear power company customers.
Joint research agreements concluded for regulatory approval of 68Ga-PSMA
On October 31, 2018, ATOX signed joint research agreements with Hokkaido University and Sumitomo Heavy Industries, Ltd. aimed at the regulatory approval of 68Ga-PSMA, a drug with the potential to deliver more effective diagnosis and treatment of prostate cancer.
ATOX wins exclusive sales rights for Galli Eo®
On February 27, 2018, ATOX signed an agreement with IRE ELiT (Belgium) giving ATOX the exclusive rights to sell the 68Ge/68Ga generator drug Galli Eo® in Japan.
R&D on lead-212 (212Pb) generator launched
On November 30, 2017, ATOX signed a joint research agreement with Riken and commenced R&D on lead-212 (212Pb) generators for use in radio isotope (RI) internal radiation therapy with α-ray emission, a promising new kind of cancer treatment.
- Top Page